Clinical Summary Resource

Share

Program Content

Activities

  • ADCs for B-Cell Lymphomas
    Antibody–Drug Conjugates for Aggressive B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2022

    Expires: June 05, 2023

  • Bispecific Abs for B-Cell Lymphomas
    Bispecific Antibodies for Aggressive B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2022

    Expires: June 05, 2023

  • BTKi for B-Cell Lymphomas
    BTK Inhibitors for Aggressive B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2022

    Expires: June 05, 2023

  • CAR T-cells for B-Cell Lymphomas
    CAR T-cell Therapy for Aggressive B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2022

    Expires: June 05, 2023

  • IMiDs and ICIs for B-Cell Lymphomas
    Immunomodulatory Agents and Immune Checkpoint Inhibitors for Aggressive B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2022

    Expires: June 05, 2023

  • Ab-Based Tx for B-cell Lymphomas
    Antibody-Based Therapies for Aggressive B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2022

    Expires: June 05, 2023

  • XPO1 Inhibitors for B-Cell Lymphomas
    XPO1 and Nuclear Export Inhibitors for Aggressive B-Cell Lymphomas: A Summary Resource
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2022

    Expires: June 05, 2023

Provided by

ProCE Banner

Supporters

AbbVie

Bristol Myers Squibb

Genmab US

Incyte Corporation

Lilly